EcoDrugPlus

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSLCAG00010012748
Gene Symbol: LOC108881770
4 Cross references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSLCAG00010011154
Gene Symbol: FLT4
1 Cross references
193 Possible Orthologues:

Folate Receptor

Ensembl ID : ENSLCAG00010021431
Gene Symbol: FOLR
4 Cross references
436 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSLCAG00010017748
Gene Symbol: FSHR
2 Cross references
198 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSLCAG00010023096
Gene Symbol: FSHR
2 Cross references
198 Possible Orthologues:

Free Fatty Acid Receptor 2

Ensembl ID : ENSLCAG00010002230
Gene Symbol: LOC108899599
3 Cross references
338 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSLCAG00010012485
Gene Symbol: FRK
4 Cross references
202 Possible Orthologues:

Galactosidase, Alpha

Ensembl ID : ENSLCAG00010001491
Gene Symbol: GLA
1 Cross references
196 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSLCAG00010007616
Gene Symbol: GABBR2
1 Cross references
208 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-2

Ensembl ID : ENSLCAG00010025231
Gene Symbol: LOC108878814
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSLCAG00010018189
Gene Symbol: GABRA1
4 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSLCAG00010020885
Gene Symbol: GABRA3
4 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).